Models of care for hepatitis C in the era of direct acting antiviral therapy

In 2014, only 1% of Australians with hepatitis C had received treatment. Low treatment rates mean that hepatitis C is a leading cause of liver cancer and liver failure. New, highly effective direct acting antiviral (DAA) treatment for hepatitis C virus infection became available in Australia in March 2016. Australia is now in the position to eliminate HCV. Key is to increase access to treatment. This thesis investigates the feasibility and effectiveness of providing hepatitis C treatment in the community.